Skip to main content

Oncolytic viruses in melanoma.

Publication ,  Journal Article
Robinson, C; Xu, MM; Nair, SK; Beasley, GM; Rhodin, KE
Published in: Front Biosci (Landmark Ed)
February 14, 2022

Malignant melanoma recurrence remains heterogeneous in presentation, ranging from locoregional disease (i.e., local recurrence, satellites, in transit disease) to distant dermal and visceral metastases. This diverse spectrum of disease requires a personalized approach to management and has resulted in the development of both local (e.g., surgery, radiation, intralesional injection) and systemic (intravenous or oral) treatment strategies. Intralesional agents such as oncolytic viruses may also evoke local immune stimulation to induce and enhance the antitumor immune response. Further, it is hypothesized that these oncolytic viruses may convert immunologically "cold" tumors to more reactive "hot" tumor microenvironments and thereby overcome anti-PD-1 therapy resistance. Currently, talimogene laherparepvec (T-VEC), a modified herpes virus, is FDA-approved in this population, with many other oncolytic viruses under investigation in both preclinical and trial settings. Herein, we detail the scientific rationale, current landscape, and future directions of oncolytic viruses in melanoma.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Front Biosci (Landmark Ed)

DOI

EISSN

2768-6698

Publication Date

February 14, 2022

Volume

27

Issue

2

Start / End Page

63

Location

Singapore

Related Subject Headings

  • Tumor Microenvironment
  • Skin Neoplasms
  • Oncolytic Viruses
  • Oncolytic Virotherapy
  • Melanoma
  • Immunotherapy
  • Humans
  • 3207 Medical microbiology
  • 3205 Medical biochemistry and metabolomics
  • 3102 Bioinformatics and computational biology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Robinson, C., Xu, M. M., Nair, S. K., Beasley, G. M., & Rhodin, K. E. (2022). Oncolytic viruses in melanoma. Front Biosci (Landmark Ed), 27(2), 63. https://doi.org/10.31083/j.fbl2702063
Robinson, Camille, Maria M. Xu, Smita K. Nair, Georgia M. Beasley, and Kristen E. Rhodin. “Oncolytic viruses in melanoma.Front Biosci (Landmark Ed) 27, no. 2 (February 14, 2022): 63. https://doi.org/10.31083/j.fbl2702063.
Robinson C, Xu MM, Nair SK, Beasley GM, Rhodin KE. Oncolytic viruses in melanoma. Front Biosci (Landmark Ed). 2022 Feb 14;27(2):63.
Robinson, Camille, et al. “Oncolytic viruses in melanoma.Front Biosci (Landmark Ed), vol. 27, no. 2, Feb. 2022, p. 63. Pubmed, doi:10.31083/j.fbl2702063.
Robinson C, Xu MM, Nair SK, Beasley GM, Rhodin KE. Oncolytic viruses in melanoma. Front Biosci (Landmark Ed). 2022 Feb 14;27(2):63.

Published In

Front Biosci (Landmark Ed)

DOI

EISSN

2768-6698

Publication Date

February 14, 2022

Volume

27

Issue

2

Start / End Page

63

Location

Singapore

Related Subject Headings

  • Tumor Microenvironment
  • Skin Neoplasms
  • Oncolytic Viruses
  • Oncolytic Virotherapy
  • Melanoma
  • Immunotherapy
  • Humans
  • 3207 Medical microbiology
  • 3205 Medical biochemistry and metabolomics
  • 3102 Bioinformatics and computational biology